Lorlatinib in ALK- and ROS1 | 合法藥品大搜索

LorlatinibinALK-andROS1-positiveNSCLC:thefuturehasastart.FrancescoFacchinetti1,LucFriboulet2.1MedicalOncologyUnit,UniversityHospitalofParma, ...

In the last decade huge improvements in prognosis and quality of life have been provided by the molecular characterization of non-small cell lung cancer (NSCLC). With particular regard to ALK- and ROS1-positive tumors, the sequential development of oral tyrosine kinase inhibitors (TKIs) has allowed survival outcomes unconceivable before their availability (1-3). ALK and ROS1 are usually approached together as lung cancer oncogenes due to their similitudes arising from the phylogenic origin, structural similarities and way of activation (i.e., by gene rearrangement) (4). The first-in-class molecule crizotinib, initially developed as a MET inhibitor, has fully shown its role in ALK- and ROS1-positive diseases. Second-generation inhibitors ceritinib, alectinib (not retaining anti-ROS1 activity) and brigatinib, administered after the onset of the unavoidable crizotinib resistance, dramatically concur to the extended patients’ survival. More recently, the third generation molecule lorlat...